Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. Safety and Efficacy of Restarting ICIs After Clinically Significant Immune-Related Adverse Events in mRCC
  2. Genomic Analysis of Translocation RCC Reveals Copy Number Variations as Drivers of Disease Progression
  3. A 2/1 Sunitinib Dosing Schedule Provides Superior Effectiveness and Less Toxicity Than a 4/2 Schedule for mRCC
  4. Efficacy of Nivolumab Plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214
  5. Survival Prognoses of Heng Intermediate-Risk Patients With mRCC Treated With Immunotherapy or Targeted Therapy
  6. Growth Rates of Genetically Defined Renal Tumors
  7. First-Line Treatment of Metastatic Renal Cell Carcinoma in the Immuno-Oncology Era
  8. Body Fat Accumulation as a Predictor of Survival Among Patients With mRCC Receiving TKIs
  9. Axitinib in First-Line for Patients With Metastatic Papillary Renal Cell Carcinoma
  10. Safety and Efficacy of Nivolumab in Patients With mRCC and Chronic HCV Infection

Elsewhere

Recently Updated